" class="no-js "lang="en-US"> £10.4m Full-service Contract Signed With Existing Big Pharma Client - Medtech Alert
Monday, May 20, 2024

£10.4m Full-service Contract Signed With Existing Big Pharma Client

Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO, a  subsidiary of Open Orphan, has signed a £10.4m contract with an existing top 5 global pharmaceutical client to manufacture a new batch of H1N1 influenza challenge virus, leveraging off an existing in-house generated challenge model, and to conduct a human challenge trial to test the client’s antiviral product. 

hVIVO has world-leading expertise in challenge agent manufacture, with the ability to manufacture specific subtypes  of viruses, as well as unrivalled experience in conducting challenge studies. Since the COVID-19 pandemic, the  Company has seen an increase in the number of clients looking to test their vaccines and antivirals against specific  subtypes of viruses that are circulating in the population or that have the potential to be widely spread. As a result,  there is a greater interest in end-to-end human challenge contracts such as this, that include a novel challenge agent  manufacture and a challenge study. 

The study will evaluate the efficacy profile of the antiviral against the specific influenza subtype, generating data  quickly and efficiently. This is the third human challenge contract signed with this client, highlighting the Company’s  world leading expertise and the clear benefits of human challenge trials to Big Pharma’s drug development process.  

Good Manufacturing Practice (“GMP”) compliant virus manufacturing activities will commence immediately and are  expected to complete by Q2 2023. Once completed, hVIVO will conduct a Phase 2a double-blinded placebo-controlled  human challenge study which is expected to be completed by Q4 2023. hVIVO will recruit healthy volunteers via the  Company’s dedicated volunteer recruitment arm, FluCamp. The majority of revenue from the contract is expected to  be recognised during 2023. 

Yamin ‘Mo’ Khan, Chief Executive Officer of Open Orphan, said: “We’re delighted to be working again with this top 5 global pharmaceutical company to test its antiviral, using a new influenza strain developed by our highly experienced  team. This contract is the third challenge study with this client, and our second end-to-end full-service contract overall.  Our one-stop shop service offerings from manufacturing bespoke challenge agents to conducting full challenge studies  is unique in the market. I am confident, that with our highly qualified teams and their clinical development expertise,  we are well placed to address the growing infectious disease and respiratory research markets. 

“Influenza poses a serious global health threat, causing an estimated 290,000 – 650,000 deaths per year with significant  pandemic potential, and as such, the development of new vaccines and antivirals to fight flu remains vitally important.” 

Dr Andrew Catchpole, Chief Scientific Officer of hVIVO, said: “This contract is a strong example of where human  challenge studies can provide significant value. These studies can quickly and cost-effectively generate efficacy data  for our clients in specific viral subtypes. As illustrated with this contract, our world-class manufacturing capabilities can  produce a challenge agent for subtypes that pose a particular global health risk or are already circulating in the  population. The resulting data can then indicate whether the candidate is viable for Phase II/III studies, providing  substantial time and financial savings compared to traditional field-based studies.” 

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more